Company News


Apeiron will present the latest research on KIF18A at AACR 2023

San Francisco

Apeiron team will attend AACR 2023 in Orlando, FL on April 18th 2023. Dr. James D. Joseph, Executive Director of biology will present our latest research on targeting the mitotic kinesin, KIF18A, i....


Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at th...


Combines precision oncology platform with single-cell sequencing and transcriptomics with aim to select patients most likely to benefit from GTAEXS-617 therapy Confirmed and identified CDK7-specific ....


Apeiron Closes $17.5 Million Series A and Launches Strategic Partnerships


GT Apeiron Therapeutics (‘Apeiron’) announced it has completed a $17.5 million Series A financing. Panacea Venture led the investment round with participation from Viva BioInnovator and existing i....


Apeiron is making its debut at AACR

San Francisco

Dr. Fred Aswad, SVP of Biology at Apeiron will present preclinical data on GTAEXS617, a novel, orally bioavailable, selective small-molecule inhibitor of CDK7 discovered using AI-driven drug discovery....


Promotion Announcement


On March 16, 2022, Apeiron's Board of Directors have come to this decision to promote Dr. Fred Aswad and Dr. Xiao-hui Gu as Senior Vice President, reporting to Dr. Mingxi Li, CEO of Apeiron. The pr....


Exscientia and GT Apeiron Therapeutics Enter Oncology Joint Venture


Combines Exscientia’s leading AI-driven drug identification and design capabilities with GT Apeiron’s expertise in cyclin-dependent kinase (CDK) targets for oncology Expands existing CDK7 drug di....


GT Apeiron Therapeutics Strengthens Advisory Board


Keith Lenden and Dr. Honggang Bi has been appointed as new members of the Advisory Board at GT Apeiron Therapeutics, an AI empowered drug discovery start-up developing oncology therapeutics. Mr....


Apeiron Therapeutics opens US headquarter

San Francisco

Apeiron Therapeutics opens US headquarter in the San Francisco Bay Area. The Bay Area office will enable Apeiron to tap into the deep expertise and talent pool at the intersection of biotechnology and....


GT Healthcare has launched GT Apeiron, an AI-driven drug development company in Shanghai


GT Healthcare Capital Partners ("GT Healthcare"), a life science-focused private equity partnership which specializes in capital investments and market scalability in Asia/ Greater China region, has l....


Apeiron announces its partnership with Exscientia


Apeiron Therapeutics is pleased to announce its partnership with Exscientia to accelerate the drug discovery process on several targets in oncology. Details of the deal are not disclosed at this time.....